(NASDAQ: AXSM) Axsome Therapeutics's forecast annual revenue growth rate of 49.34% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.37%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.15%.
Axsome Therapeutics's revenue in 2026 is $708,236,000.On average, 23 Wall Street analysts forecast AXSM's revenue for 2026 to be $51,194,748,205, with the lowest AXSM revenue forecast at $43,753,151,444, and the highest AXSM revenue forecast at $59,178,730,900. On average, 23 Wall Street analysts forecast AXSM's revenue for 2027 to be $84,496,935,772, with the lowest AXSM revenue forecast at $70,345,500,122, and the highest AXSM revenue forecast at $108,631,566,026.
In 2028, AXSM is forecast to generate $122,216,944,250 in revenue, with the lowest revenue forecast at $85,526,131,092 and the highest revenue forecast at $190,246,754,902.